| Revenue growth | 15.66% YoY for FY26. |
|---|---|
| Margins | EBITDA margin softened to 8.56% in FY26 vs 10.64% in FY25. |
| Demand visibility | Strong volume growth in regulated markets. |
| Management confidence | High, citing strong regulatory compliance and capacity enhancements. |
Growth
FY26 Revenue rose 15.7% to ₹776 Cr; EBITDA grew 6.5% to ₹67.84 Cr; Total Production up 25% to 1733 MT.
Outlook
Capacity expanded to 2400 MTPA; focus on niche APIs, process innovation, and increasing export share in regulated markets.
Risks
Global market challenges impacted Q4 profitability; currency risks mentioned regarding export dependency.
Earnings Call filed with BSE, NSE: ANUHPHR. Summary written with AI assistance from the document.
Anuh Pharma Ltd: key numbers
- Share price
- ₹90.42
- Market cap
- ₹906.2 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 20.5×Sector 50.4×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Investor Presentation: Key Takeaways
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
- Call
- Guides 18% growth
Anuh Pharma Q1 FY27 Results: Net Profit ₹11.4 Cr, Up 37.3% YoY
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹11.4 Cr · +37.3% YoY
Anuh Pharma Q4 FY26 Results: Net Profit ₹11.7 Cr, Down 6.4% YoY
Anuh Pharma Ltd reported revenue from operations of ₹202.1 Cr (+2.0% YoY) and net profit of ₹11.7 Cr (-6.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹11.7 Cr · -6.4% YoY